Sind Lennox Gasteau

Cochrane Database Syst Rev. 2003;(3):CD003277.
Treatment of Lennox-Gastaut syndrome.
Hancock E, Cross H.
Source
c/o Room 2.28 Clinical Science Centre for Research & Education, Lower Lane,Liverpool, Merseyside, UK, L9 7LJ.
Update in
* Cochrane Database Syst Rev. 2009;(3):CD003277.
Abstract
BACKGROUND:
The Lennox-Gastaut syndrome is an age-specific disorder, characterised byepileptic seizures, a characteristic electroencephalogram (EEG), psychomotor delay and personality disorders. It occurs more frequently in males and onset is usually before the age of eight with a peakbetween three and five years. Late cases occurring in adolescence and early adulthood have rarely been reported. Language is frequently affected with both slowness in ideation and expression in additionto difficulties of motor dysfunction. Severe behavioural disorders (for example hyperactivity, aggressiveness and autistic tendencies)and personality disorders are nearly always present. There isalso a tendency for psychosis to develop with time. The long-term prognosis is poor; although the epilepsy often improves, complete seizure freedom is rare and conversely the mental and psychiatricdisorders tend to worsen with time.
OBJECTIVES:
To compare the effects of pharmaceutical therapies used to treat Lennox-Gastaut syndrome in terms of control of seizures and adverse effects. Many peoplewho suffer from this syndrome will already be receiving other antiepileptic medications at the time of their entry into a trial. However, for the purpose of this review we will only consider theeffect of the single therapeutic agent being trialed (often as add-on therapy).
SEARCH STRATEGY:
We searched the Cochrane Epilepsy Group trials register (March 2003), MEDLINE (1966 to March 2003) andEMBASE (1980 to March 2003). In addition, we contacted pharmaceutical companies and colleagues in the field to ascertain any unpublished/ongoing studies.
SELECTION CRITERIA:
All randomised...